Notícias

RapAdmin

MaravirocImmune
MaravirocImmune2752×1536 364 KB

As mammals age, the immune system becomes increasingly biased toward producing myeloid cells over lymphoid cells, driving chronic systemic inflammation and elevating the neutrophil to lymphocyte ratio. This paper demonstrates that bone marrow infiltrating CD4+ T cells acquire mitochondrial dysfunction over time, which activates the cGAS-STING pathway and triggers the secretion of the signaling protein CCL5. This protein binds to CCR5 receptors on hematopoietic stem cells, forcing them to overproduce neutrophils. Pharmacological blockade of the CCR5 receptor using the FDA approved antiviral drug maraviroc reversed this myeloid skewing, normalized circulating immune profiles, and significantly improved physical strength and motor coordination in aged mice.

The neutrophil-to-lymphocyte ratio is one of the least glamorous numbers on a standard blood panel. It costs nothing extra, falls out of any complete blood count, and predicts death from nearly every age-associated disease studied. It also climbs steadily with age. Until now the reason it climbs has been largely a matter of description rather than mechanism.

A team led by María Mittelbrunn and Enrique Gabandé-Rodríguez at the Centro de Biología Molecular Severo Ochoa in Madrid, working with collaborators across Spain, Italy, Switzerland, Germany, and the US National Institute on Aging, has now traced a specific causal chain. The culprit is a type of T cell that should not really exist in large numbers. CD4+ T cells are conventionally the coordinators of immunity, not the assassins. But with age a subset acquires the killing machinery of CD8+ cells: perforin, granzymes, the transcription factor EOMES. These cytotoxic CD4+ cells have been noted in aged humans and in supercentenarians, and their significance has been argued about for years.

The Madrid group found these cells piling up specifically in bone marrow. When they transferred T cells from old mice into young T-cell-deficient recipients, myeloid output jumped within seven days. Transfer young T cells instead and nothing much happens. The bone marrow, it turns out, is where these cells preferentially accumulate, more than spleen, liver, fat, or colon.

The mechanism runs through the mitochondria. Persistent antigenic stimulation wrecks mitochondrial function in these cells. Damaged mitochondria spill DNA into the cytosol, where the cGAS-STING pathway reads it as an infection signal and switches on CCL5 production. Mice engineered to have broken mitochondria only in their T cells developed the same picture at eight months of age that normal mice reach at twenty-four. That is a compression of roughly two-thirds of the mouse lifespan into a single genetic lesion, which is a strong argument that the mitochondrial defect is upstream rather than incidental.

The receiving end matters too. Aged hematopoietic stem cells and granulocyte-monocyte progenitors upregulate CCR5. In elegant competitive chimera experiments where half the marrow could see CCL5 and half could not, only the CCR5-competent progenitors expanded when old T cells arrived. The signal is being received, not merely broadcast.

The translational hook is that a CCR5 blocker already sits on pharmacy shelves. Maraviroc has been approved for HIV since 2007. One month of daily injections in old mice pushed the NLR back toward youthful levels, reduced neutrophils infiltrating lung and liver, and improved a spread of physiological markers. Young mice given the same drug showed essentially no change, which suggests the drug corrects a pathological signal rather than broadly suppressing immunity.

Actionable Insights

For individuals focused on longevity therapeutics, this paper provides highly practical value regarding the neutrophil to lymphocyte ratio (NLR). This ratio is easily obtained from standard complete blood count panels and serves as a highly sensitive, low cost proxy for systemic aging and bone marrow niche health. In large human cohorts a rising NLR ratio tracks with mortality risk across cardiovascular disease, cancer, and infection. This study supplies a mechanistic reason to take that number seriously rather than treating it as noise, because in mice the ratio is not a passive readout but a consequence of an active signaling loop that can be interrupted.

The application of a CCR5 inhibitor successfully lowered this ratio and reversed associated physical decline. In the study, 23 month old mice treated with maraviroc experienced an approximate 39 percent reduction in their neutrophil to lymphocyte ratio, dropping from a median of 0.33 to 0.20. This intervention generated physical improvements with substantial effect sizes. Grip strength increased by roughly 25 percent, representing an absolute gain of approximately 15 grams of force compared to vehicle treated controls. Furthermore, motor coordination measured by rotarod latency improved dramatically, with treated mice remaining on the apparatus for roughly 100 to 150 seconds longer than untreated age matched controls.

Maraviroc carries a black box warning for liver toxicity in humans. While maraviroc is currently available, it carries immunosuppressive risks that require careful clinical management.

Context and Source

  • Open Access Paper: Cytotoxic CD4+ T cells induce age-associated myelopoiesis through CCL5–CCR5 signaling
  • Primary institution: Centro de Biología Molecular Severo Ochoa (CSIC-Universidad Autónoma de Madrid), Madrid, Spain. Corresponding authors Enrique Gabandé-Rodríguez and María Mittelbrunn.
  • Country: Spain (lead), with international consortium.
  • Journal: Nature Aging (Springer Nature)
    Dates: Published online 26 August 2026.
  • Impact evaluation: The impact score of this journal is 25.0 (2025 two-year Journal Impact Factor; five-year JIF 26.0), evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

AntlerRejuvenation-2
AntlerRejuvenation-22752×1536 428 KB

The research paper demonstrates that extracellular vesicles derived from antler blastema progenitor cells can reverse multiple signs of systemic aging in both rodents and nonhuman primates. Researchers isolated these vesicles from regenerating deer antlers and injected them intravenously into aged mice and elderly rhesus macaques. The treatment significantly increased bone mineral density, improved cognitive and motor function, reduced systemic inflammation, and reversed blood-based epigenetic age clocks. The primary mechanism of action relies on the transfer of specific messenger RNA payloads, notably Prkar2a, which restores youthful cellular function and reduces cellular senescence.

Nature has engineered a highly efficient regeneration machine in the form of deer antlers. Mammalian organs typically lose their regenerative capacity shortly after birth, but deer antlers are the exception. These bony structures can regenerate completely every single year, growing at a remarkable rate of up to 2.75 centimeters per day. The biological drivers behind this extreme growth are antler blastema progenitor cells. A consortium of researchers in China successfully cultured these cells and extracted their extracellular vesicles, testing whether the regenerative signals contained within could be transferred to entirely different species.

The resulting study represents a major shift in systemic rejuvenation research. Most current longevity interventions focus on metabolic restriction or the selective destruction of senescent cells. This intervention uses cross-species cellular communication to force old cells to adopt youthful expression profiles. The researchers injected the antler-derived vesicles into 18-month-old mice and 16 to 18-year-old rhesus macaques. The physiological changes were profound and systemic. In mice, the vesicles reversed bone loss, increased fatigue resistance on treadmills, and improved spatial memory. In the macaque cohort, the treatment resulted in increased spontaneous physical activity, improved manual dexterity, and a measurable increase in total intracranial brain volume.

The active ingredients driving these biological changes are the messenger RNA payloads encapsulated within the vesicles. The researchers identified Prkar2a as a primary geroprotective factor. When the vesicles fuse with aged host cells, this RNA is translated into a regulatory subunit of the PKA holoenzyme, which subsequently triggers downstream longevity pathways, reduces oxidative stress, and halts the senescence-associated secretory phenotype.

While cross-species vesicle transfer sounds inherently risky regarding immune rejection, the study reported no adverse immunological reactions in the treated animals. This suggests that stem cell-derived extracellular vesicles might bypass the histocompatibility barriers that normally plague cell therapies. The ability to freeze, store, and inject these vesicles without triggering severe immune responses positions them as a highly scalable alternative to traditional stem cell transplantation.

Actionable Insights

For individuals focused on human longevity, the immediate translation of this research requires careful interpretation. The study proves that systemic rejuvenation via extracellular vesicles is biologically possible in primates, but commercial antler products like oral deer velvet supplements will not replicate these results. Extracellular vesicles and their fragile RNA payloads are destroyed in the human digestive tract.

The most practical insight is the identification of Prkar2a and the PKA pathway as primary targets for reducing cellular senescence. The magnitude of the observed benefits is substantial. In mice, bone mineral density in the femur increased by 150 percent (a 2.5-fold increase) compared to untreated controls, shifting skeletal profiles from osteoporotic to youthful. Epigenetic aging clocks derived from blood methylation showed a reversal of 3.54 months in mice and 2.14 years in elderly macaques. For a macaque, 2.14 years represents roughly 8.5 percent of its total maximum lifespan of 25 years. Until intravenous delivery of standardized, purified stem cell vesicles becomes clinically available, biohackers should focus on existing interventions known to modulate PKA signaling and macroautophagy to achieve similar downstream reductions in systemic inflammation.

Context and Source

RapAdmin

MitoExerciseImpact
MitoExerciseImpact1920×1072 312 KB

This narrative review from Chinese researchers asks one question: how does exercise slow aging in the organs that burn the most energy? Those are skeletal muscle, liver, brain, kidney and heart. The authors argue that the answer is mitochondrial quality control. Exercise switches on the AMPK and PGC-1alpha signals that build new mitochondria. It balances fusion and fission, clears out damaged mitochondria through mitophagy, and limits the oxidative, inflammatory and apoptotic signals that come from failing mitochondria. The review is a map of possible mechanisms, drawn mostly from rodent studies. Where human data exist, they point the same way.

Narrative

Your liver burns about 200 kilocalories per kilogram of tissue each day. Your heart and kidneys burn about 440, and your brain about 240. Resting skeletal muscle burns only about 13. These organs run almost entirely on mitochondria, which makes them among the first to suffer when mitochondria wear out. A new review in iScience argues that exercise is still the most reliable tool we have to slow that wear, and that it acts on the same basic machinery in every organ.

The shared mechanism goes like this. Hard muscular work drains ATP, and the rising ratio of AMP to ATP switches on AMPK, the cell’s fuel gauge. AMPK activates PGC-1alpha, a master regulator that turns on the genes for building new mitochondria and copying their DNA. Exercise also changes mitochondrial shape. Endurance work tends to favor fusion, which joins mitochondria into networks that share healthy components. Resistance work and high intensity tend to favor fission, which splits damaged pieces off so the cell can destroy them through mitophagy. The result is more mitochondria, and better ones.

The authors then go through five organs. In aged rodent muscle, training restores respiratory capacity and mitophagy. In the liver, eight weeks of treadmill running in 21-month-old rats lowered oxidative DNA damage to levels seen in rats half their age. In the brain, swimming and resistance programs in old rats restored hippocampal mitochondrial signaling alongside better memory scores. In the kidney, exercise suppressed fibrosis pathways and turned on the protective Klotho and NRF2 systems. In the heart, it improved calcium handling and cut mitochondria-driven cell death.

Human data are thinner but consistent. In the LIFE randomized trial, which followed about 1,200 sedentary adults aged 70 to 89, two years of walking plus strength work slowed kidney function decline by roughly 1 unit of eGFR. In a Taiwanese cohort of nearly 200,000 adults, the most active people lost kidney function about 40 percent more slowly each year than the least active.

The review is also candid about the limits. Too much exercise backfires. Exhaustive or high-intensity bouts in old animals raised oxidative damage in the heart and triggered brain inflammation. Some studies found no benefit at all, including one on old rats with kidney disease. The gains also fade quickly. Older adults lost their training-induced mitochondrial enzyme activity faster than young adults after they stopped. Forced exercise in rodents generally did worse than voluntary running, and sex, hormones and baseline fitness all changed the results.

The review’s value is its cross-organ framing. Aging does not strike one organ at a time, and exercise does not act on one organ at a time either. Its weakness is that it catalogues associations without weighing them. It does not rank studies by quality, run a meta-analysis, or say which pathway matters most. For the field, the message is not that exercise works. We knew that. The message is that mitochondrial quality control may be the common currency, and that dosing by age, and possibly by organ, is the unsolved problem.

Actionable Insights

The best-supported human protocols in the review are modest. Around 150 minutes of brisk walking per week plus light strength work, which was the LIFE trial design, cut the share of older adults with rapid kidney decline from 32.2 percent to 25.9 percent. That is about 6 fewer people with fast decline per 100 people exercising, roughly a 20 percent relative reduction. Put another way, about 16 people need to exercise for two years to spare one person from rapid decline. Average kidney function was 0.96 eGFR units better after two years. That is real but small, about one year’s worth of normal age-related loss.

In the population data, highly active adults lost 0.27 eGFR units a year versus 0.46 for the least active, and they had about 9 percent lower risk of developing chronic kidney disease. Because this was observational, part of that gap may reflect healthier people choosing to exercise.

For muscle, 10 weeks of full-body resistance training twice weekly (3 sets of 10 to 12 reps) raised mitochondrial respiratory complex levels in adults around 59. The practical rules are these: combine aerobic and resistance training, avoid chronic exhaustive sessions after middle age, and never stop. Older muscle loses its mitochondrial gains faster once training ends.

Context and Source

  • Open Access paper: Exercise-induced mitochondrial remodeling in energy-demanding organs during aging
  • Institutions: Anhui University of Chinese Medicine (Hefei) and Wuhan Sports University (Wuhan)
  • Country: China
  • Journal: iScience (Cell Press), published August 21, 2026
  • Impact evaluation: The impact score of this journal is 4.5 (JIF), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

MusclesTestosterone
MusclesTestosterone2752×1536 428 KB

French researchers deleted the androgen receptor (AR) only in the muscle stem cells (satellite cells) of adult male mice. The muscles still healed after injury, but they healed worse. Fibers came out smaller and disorganized, there was more scar tissue and fat, and force was about 13% lower. The stem cells also stopped renewing themselves properly. Too many of them committed to becoming muscle at once, and after a second injury the reserve pool was about three times smaller than normal. In male mice, testosterone falls sharply by one year of age, and muscle AR protein falls with it. Older mice given a DHT implant repaired injured muscle with about a third less fibrosis. The stem cell pool itself did not recover.

Muscle carries its own repair crew. Satellite cells sit dormant under the surface of each muscle fiber. When the muscle is damaged, some of them wake up and rebuild it, and the rest go back to sleep so they are available next time. That balance between spending and saving stem cells is what makes muscle repair last a lifetime. It is also a big part of why older muscle heals badly.

This study, from the IGBMC institute near Strasbourg, points to testosterone signaling as one of the things that holds the balance. The team removed the androgen receptor, the protein that lets cells respond to testosterone and DHT, from satellite cells alone. They did it in young adult male mice, so every other tissue could still sense hormones normally.

Without injury, nothing obvious happened. After the team damaged a leg muscle with snake toxin, the knockout mice repaired it poorly. New fibers were smaller and structurally messy, inflammation lasted longer, scar tissue roughly doubled, and fat cells showed up where muscle should have been. Stem cell numbers were about half of normal one week after injury. After a second injury, they were about a third of normal.

The mechanism looks like poor rationing. AR is concentrated in the most dormant stem cells. When it is missing, those cells leave dormancy early and too many of them become committed muscle cells. The reserve gets used up. Molecular maps show AR moving around the genome during repair. It first sits near genes that keep stem cells dormant, then moves to genes for activation, and later to genes for maturation. The knockout cells also switched early to mitochondrial energy production, a metabolic sign that they had left the resting state.

The link to aging matters most here. Testosterone in these male mice fell from about 25 to about 3 to 5 nmol/L by one year of age, and AR protein in muscle dropped by nearly 80%. Aged normal muscle healed in a way that looked partly like the young knockouts. Aged knockouts did worse still. When 21-month-old mice received DHT implants, their repaired muscle had fewer scar-tissue regions and more nuclei per fiber. Stem cell counts did not change, and no one measured strength.

Human cells gave a similar picture. A muscle-precursor line from an older man had about half the AR of a line from a younger man and differentiated less well. Knocking AR down stopped differentiation in both lines. Adding extra AR sped up differentiation in the older line.

The big idea is that testosterone does more than build muscle mass. Acting on stem cells, it may help decide whether muscle can keep repairing itself over decades. That shifts the discussion of male hormonal decline from how big the muscles are to how well they can repair. The evidence comes from a small number of mice, all male, and one injury model, so it is a strong hypothesis rather than a settled mechanism.

Actionable Insights

This is a mechanistic mouse study, not a treatment trial. Its lessons are directional.

  1. Male hormone decline may matter most for repair. In these mice, testosterone fell by roughly 80 to 90% with age. When androgen signaling in stem cells was removed, recovery after injury was worse: about 13% less force, twice the scar tissue and three times fewer stem cells after re-injury. For older men, it is reasonable to track total and free testosterone and not only muscle size. [Confidence: Medium]
  2. Restoring hormones only partly fixed the problem. In old mice, DHT cut scar tissue in repaired muscle from about 22% to about 15% of the area, a relative reduction of about 36%. It did not restore the stem cell pool, and no strength data were collected. That is a modest, partial repair signal. It is not evidence that TRT or DHT reverses muscle aging. [Confidence: Low for translation]
  3. Do not self-prescribe androgens because of this paper. Outside androgens shut down the body’s own testosterone production and carry blood, fertility and prostate risks. Decisions about testosterone therapy belong with a clinician.
  4. Men on anti-androgen drugs, such as prostate cancer therapy, may have slower muscle repair. This is a hypothesis only.
  5. Women were not studied.

Context and Source

RapAdmin

ThymulinReduction
ThymulinReduction2752×1536 415 KB

Chronic inflammation increases with advancing age and actively drives cancer progression while blunting the efficacy of medical treatments. This study identifies thymulin, a naturally occurring peptide produced by the thymus gland, as a critical systemic regulator that suppresses pro-inflammatory immune cells. Because thymic function and thymulin levels decline with age, older individuals suffer from unrestrained immune activation. Supplementing older subjects with thymulin successfully reduced systemic inflammation, slowed tumor growth, and restored the effectiveness of immune checkpoint inhibitors.

Aging fundamentally rewires the immune system. A primary hallmark of this biological decline is inflammaging, a persistent state of low grade systemic inflammation. This sterile inflammation is driven by the overactivity of myeloid cells, which overproduce specific cytokines including interleukin 1 alpha, interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. This highly reactive environment degrades healthy tissue function, acts as a catalyst for cancer progression, and severely blunts the efficacy of modern immunotherapies.

Researchers sought to decode the precise mechanisms governing this age related inflammatory surge. They mapped the immune profiles of young and aged mice, identifying a massive expansion of pro-inflammatory myeloid cells in the older cohort. To determine if this state was fixed or reversible, the team surgically connected the circulatory systems of young and old mice in a procedure known as heterochronic parabiosis. Exposure to youthful blood rapidly suppressed the inflammatory activation of aged myeloid cells, proving that circulating systemic factors dictate the immune aging phenotype.

To isolate the exact origin of this inflammatory dysregulation, the researchers utilized heterochronic bone marrow chimeras. They transplanted aged bone marrow into young mice and young bone marrow into aged mice. The host environment, rather than the intrinsic age of the bone marrow cells, dictated the inflammatory output. Aged immune cells placed in a young host environment ceased their overproduction of inflammatory cytokines. This proved that a circulating factor produced by non bone marrow tissues in young animals was responsible for keeping the immune system regulated.

Through rigorous pathway analysis, the researchers traced the source of these youthful circulating factors to the thymus. The thymus is an organ that shrinks and loses cellular function early in life. They identified thymulin, a thymus derived peptide, as the critical mediator. Thymulin levels are high in youth but drop precipitously with advancing age. When researchers administered daily thymulin injections to aged mice, the treatment halved the frequency of circulating inflammatory myeloid cells. At the molecular level, thymulin achieves this by blocking the NF-kB signaling pathway, effectively turning off the genetic switches that produce inflammatory cytokines.

The clinical implications for oncology are profound. In preclinical breast cancer models, aged mice exhibited accelerated tumor growth and zero survival response to standard anti-PD-L1 immunotherapy. However, when aged mice received thymulin, tumor growth slowed significantly. Furthermore, thymulin conditioning sensitized the tumors to immunotherapy. The combination of thymulin and immune checkpoint blockade extended survival in older mice, effectively rescuing their immune systems from age related dysfunction. This research pivots the focus of immune rejuvenation from complex cellular reprogramming to practical endocrine restoration.

Actionable Insights

For individuals focused on extending healthspan, this study highlights the critical role of thymic health in controlling systemic inflammation. The thymus functions as an endocrine organ that keeps innate immune cells from turning chronically destructive.

The primary takeaway is that age related immune dysfunction is biochemically reversible. Supplementing the aged immune system with thymulin reversed the inflammatory output of myeloid cells by approximately 50 percent. In practical terms, treating older mice with thymulin reduced the population of circulating cells producing tumor necrosis factor alpha from nearly 20 percent down to 10 percent. This absolute reduction of 10 percentage points represents a massive relative drop, cutting the systemic inflammatory burden in half.

Furthermore, thymulin administration increased median survival times in aged tumor bearing mice by over 25 percent even without concurrent therapies. When combined with immunotherapy, survival extensions were highly pronounced. While direct human thymulin supplementation requires clinical trials, these findings validate interventions that preserve thymic mass. Nutritional and lifestyle practices that delay thymic involution may indirectly sustain endogenous thymulin production, thereby suppressing inflammaging and mitigating associated disease risks.

Context and Source

RapAdmin

Sirt3Rejuvenation-2
Sirt3Rejuvenation-22752×1536 442 KB

A new study demonstrates that the biological origin of age-related systemic inflammation lies within the hematopoietic stem cells of the bone marrow. Researchers found that the mitochondrial deacetylase SIRT3, which normally declines with age, acts as a critical brake against maladaptive immune memory, and overexpressing it in these stem cells prevents age-related tissue decline.

The underlying biological driver of systemic aging is chronic, sterile inflammation. While researchers have long observed rising circulating cytokines in older populations, the exact cellular origin of this phenomenon has remained elusive. This paper provides compelling evidence that hematopoietic stem cells are a primary source of this aging cascade. Over a lifetime, these stem cells are exposed to repeated inflammatory insults and stress signals. In response, they undergo epigenetic rewiring to launch faster, stronger immune responses in the future, a phenomenon known as trained immunity. While beneficial for fighting acute infections in youth, this immune memory becomes highly maladaptive in older age, resulting in a persistent overproduction of myeloid cells that flood distant organs with inflammatory signals.

The research team identified the mitochondrial enzyme SIRT3 as the critical off-switch for this maladaptive training. SIRT3 expression naturally drops as organisms age, leading to increased mitochondrial oxidative stress within the stem cell niche. This metabolic shift forces the stem cells to adopt an inflammatory epigenetic program. By engineering mice to maintain high SIRT3 expression specifically in their hematopoietic stem cells, the researchers successfully blocked this aging response. The stem cells of these engineered mice produced progeny with a regulatory, rather than inflammatory, phenotype.

The downstream physiological effects of correcting this stem cell defect were massive. Restoring SIRT3 in the bone marrow did not just improve blood biomarkers; it actively rescued distant tissue function. Aged mice with SIRT3 overexpression exhibited significantly fewer inflammatory macrophages infiltrating their muscles and lungs. Consequently, they maintained youthful muscle endurance, preserved cognitive function, and showed improved glucose tolerance compared to normal aged mice. When researchers transferred just the spleen cells from old normal mice into young mice, the young mice rapidly developed systemic inflammation and muscle weakness. This definitively proves that circulating immune cells serve as the primary vector for age-related physical decline.

Actionable Insights
The fundamental takeaway is that the immune system’s memory of past stress turns maladaptive as we age, driving the chronic inflammation that degrades tissue function. For individuals optimizing their healthspan, this highlights the necessity of preventing mitochondrial dysfunction in the immune compartment.

The magnitude of this intervention is substantial. In the study, two-year-old mice with maintained SIRT3 expression exhibited an absolute reduction in circulating IL-6 from approximately 120 pg/ml down to 15 pg/ml, representing an 87 percent relative decrease. The phenotypic rescue was equally striking. In treadmill exhaustion tests, the aged engineered mice ran for approximately 300 meters compared to just 110 meters for normal aged controls, which translates to a 172 percent relative improvement in physical endurance.

While direct genetic engineering of stem cells is not yet clinically available, maintenance of cellular NAD+ pools via precursors like niacinamide is mechanistically adjacent to optimizing sirtuin activity. Monitoring downstream inflammatory biomarkers like IL-6 and high-sensitivity C-Reactive Protein provides a practical method to track maladaptive immune states within a Medicine 3.0 prevention framework. Furthermore, the profound preservation of treadmill endurance in these models strongly supports maintaining high-frequency cardiovascular conditioning to offset age-related macrophage infiltration and functional decline in muscle tissue.

Context and Source

  • Open Access Paper: Trained immunity links hematopoietic stem cell aging to aging-associated inflammation, Published: 16 July 2026.
  • Institution: University of California, Berkeley; Buck Institute for Research on Aging; Radboud University Medical Center; University of Bonn, among others.
  • Country: United States, Netherlands, Germany
  • Journal: Nature Aging
  • Impact Evaluation: The impact score of this journal is 16.6, evaluated against a typical high-end range of 0 to 60 for top general science, therefore this is a High impact journal.

RapAdmin

IL11FatFemaleLongevity-2
IL11FatFemaleLongevity-22752×1536 360 KB

Researchers analyzed tissue from 22-month-old mice to determine why seven prominent anti-aging drugs extend lifespan exclusively in males. The study measured levels of the pro-inflammatory cytokine interleukin-11 across liver, muscle, and adipose tissues. While the drugs successfully lowered interleukin-11 in subcutaneous fat for both sexes, they triggered divergent responses in visceral fat. In males, the interventions suppressed visceral interleukin-11, but in females, five of the seven drugs paradoxically increased it. This dimorphic inflammatory response in abdominal fat suggests a compelling mechanism for the male-exclusive lifespan benefits observed in previous pharmacological trials.

The pharmacological extension of mammalian lifespan faces a persistent and poorly understood hurdle involving sexual dimorphism. The Interventions Testing Program has identified multiple compounds that extend lifespan in male mice while failing to benefit females. This phenomenon limits the clinical translation of these longevity therapeutics.

A specific protein called interleukin-11 acts as a primary driver of age-related inflammation and fibrosis. Earlier research established that blocking interleukin-11 signaling directly extends mammalian lifespan. Building on this foundation, investigators hypothesized that male-specific longevity compounds might operate by suppressing this inflammatory cytokine.

The research team tested tissue from aged mice treated with seven known male-specific longevity drugs. These drugs included canagliflozin, epicatechin, mitoglitazone, halofuginone, astaxanthin, meclizine, and 16-alpha-hydroxyestradiol. The investigators measured interleukin-11 protein levels across liver, skeletal muscle, subcutaneous fat, and visceral perigonadal fat.

The results revealed absolute tissue specificity. None of the seven drugs altered interleukin-11 expression in liver or skeletal muscle. In subcutaneous inguinal fat, the treatments universally reduced the inflammatory cytokine in both male and female subjects.

The critical discovery occurred in visceral perigonadal fat. Six of the seven drugs induced severe sex-specific divergence. Male mice experienced a significant reduction in visceral interleukin-11. Conversely, female mice experienced a paradoxical elevation of the cytokine.

Visceral adipose tissue acts as a central regulatory node for systemic metabolic health. The data indicates that while these pharmaceutical interventions successfully mitigate subcutaneous fat inflammation, they trigger a compensatory inflammatory cascade in female visceral fat. This localized tissue inflammation likely counteracts any systemic benefits the drugs might otherwise provide to females, fully negating potential lifespan extension.

Actionable Insights

Biohackers and clinicians must treat male-specific longevity compounds with caution regarding female longevity protocols. The magnitude of the dimorphic response can be substantial. In male subjects, drugs like mitoglitazone and 16-alpha-hydroxyestradiol reduced visceral interleukin-11 by 50 to 80 percent, demonstrating a massive anti-inflammatory effect size.

For female subjects, the exact same interventions increased visceral interleukin-11 by 20 to 100 percent. Halofuginone doubled the inflammatory marker in female visceral fat. This represents a significant pro-inflammatory insult.

Females utilizing compounds like astaxanthin, epicatechin, or canagliflozin for generalized anti-aging purposes may inadvertently accelerate visceral adipocyte inflammation.

Context/Source

RapAdmin

MVX
MVX2752×1536 388 KB

I’m a little slow to get on the MVX bandwagon after @qBx123Yk alerted us to in his initial MVX post here in August - but I finally listened to the Peter Attia Podcast interview with Dr. James (Jim) Otvos, and I’m intrigued. The key bit of information from that podcast that catches your attention is this:

Chronological Age-Independence of MVX: Baseline MVX score distributions in 25-to-30-year-old adults (CARDIA cohort) are nearly identical to distributions in 60-year-old cohorts (MESA) and independently predict 30-year premature mortality in disease-free individuals.

In other words, it doesn’t seem that this measure is related to age, and yet it can predict premature mortality risk decades in advance, in seemingly healthy younger people.

The test is available for $40 from “Own Your Own Labs” - more info here (we have no affiliation with this company, its just the cheapest price we’ve found for this test).

So - this seems like a collection of tests (the MVX tests) that I want to learn about. So I’m creating this thread just to cover the research papers that have been done on this MVX index. This is all very new; the first paper was published in 2023, and there are not that many papers (less than a dozen it seems, but most of them seem to be from the past year or two. So - I’ll start with the initial 2023 paper his by Dr. Otvos and his team, then cover the others.

A Blood Test That Sees Malnutrition and Inflammation at the Same Time

Researchers at the National Heart, Lung, and Blood Institute and Mayo Clinic applied a composite blood score called the Metabolic Vulnerability Index (MVX) to 1,382 heart failure patients drawn from an entire county’s medical records, then followed them for a median of 13.9 years. MVX is measured by a single nuclear magnetic resonance scan of plasma and combines two things that usually get measured separately: a marker of systemic inflammation and a set of markers reflecting protein-energy malnutrition. Patients in the highest MVX quartile died roughly three times as fast as those in the lowest, and that gap held after adjusting for age, sex, and the standard MAGGIC risk score.

For twenty years, cardiologists have argued about the “cytokine hypothesis” of heart failure: the idea that a failing heart is not simply a pump problem but a whole-body inflammatory and wasting disease. Patients lose muscle. They lose appetite. Their blood fills with signals of chronic immune activation. The problem has always been that these processes get measured one marker at a time, and no single marker has been convincing enough to change what doctors do on a Tuesday afternoon.

The Metabolic Vulnerability Index takes a different approach. A single nuclear magnetic resonance scan of a plasma sample reads out six things at once: GlycA, a signal arising from the sugar groups on acute-phase proteins, and small high-density lipoprotein particles, which together form an inflammation sub-score; plus citrate and the three branched-chain amino acids leucine, isoleucine, and valine, which form a malnutrition sub-score. The six are combined into one number from 1 to 100. Higher means more vulnerable (or more “metabolically frail”, as Jim Otvos has suggested we should think of it as).

This is the first time the score has been tested in heart failure, and the cohort is unusually good. Rather than recruiting from a specialist clinic or a drug trial, the team used the Rochester Epidemiology Project, a records linkage system that captures nearly every medical encounter in three Minnesota counties. That means the cohort looks like heart failure as it actually occurs, not as it appears after trial eligibility criteria have filtered out the old and the complicated. Median age was 78. Just over half had preserved ejection fraction. More than two-thirds were in NYHA class III or IV.

The results were graded and consistent. Death rates rose stepwise across the four MVX groups, from 7.3 per 100 patient-years in the lowest to 22.6 in the highest. Five-year mortality went from 23.5 percent to 69 percent. The relationship with mortality was linear across the whole range of scores, with no threshold effect.

The more interesting finding is what the score was not tied to. MVX showed no relationship with ejection fraction, the measure that currently sorts heart failure into its major treatment categories. Nor did it track closely with physical frailty; a companion study in the same cohort found the two correlate weakly and that MVX explains only a few percent of frailty’s mortality signal. Whatever MVX is detecting, it appears to sit in a different lane from both the pump and the patient’s visible condition.

The honest accounting comes when the statistical adjustments pile up. The near-threefold crude difference shrinks to about 1.5-fold once the MAGGIC score, NT-proBNP, and hemoglobin are all in the model. Added to a model already containing those three, MVX moved the concordance statistic from 0.71 to 0.72.

So the result cuts both ways. It supports the biology: inflammation and wasting carry mortality information that ejection fraction and natriuretic peptides do not capture. Two of the authors work for the commercial laboratory that owns the assay, the scoring algorithm is proprietary, and a follow-up study found MVX did not move measurably over twelve months, including in patients on active drug treatment.

Actionable Insights

Nothing here is a therapy. MVX is a risk label, and a follow-up study found it barely moved over a year even under active treatment, so lowering your score is not currently a demonstrated goal. What is useful is seeing which underlying markers did the separating, because those map onto things you can already measure and influence.

Small HDL particles separated the best and worst groups most sharply. Median 13.7 in the healthiest quartile versus 4.6 micromol/L in the sickest, a standardized gap of roughly 2.8 standard deviations, which is very large. Valine came next at about 1.7, GlycA at 1.1, and leucine at 1.3.

Note the direction on the amino acids. In metabolic syndrome research, high branched-chain amino acids signal insulin resistance. Here the opposite pattern carries the risk: low leucine, isoleucine, and valine, consistent with muscle catabolism. In an older, sick population, falling amino acids indicate you are burning your own tissue.

The practical reading: adequate protein intake and resistance training to defend muscle mass, and attention to chronic inflammation, are supported by the direction of these associations. They are not proven by this study, which was observational and tested no intervention.

Context and Source

  • Open Access Paper: The Metabolic Vulnerability Index: A Novel Marker for Mortality Prediction in Heart Failure, Published 2023 Jul 19.
  • Authors: Conners KM, Shearer JJ, Joo J, Park H, Manemann SM, Remaley AT, Otvos JD, Connelly MA, Sampson M, Bielinski SJ, Wolska A, Turecamo S, Roger VL
  • Institutions: National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; Mayo Clinic, Rochester, Minnesota; LabCorp, Morrisville, North Carolina; NIH Clinical Center Department of Laboratory Medicine
  • Country: United States
  • Journal: JACC: Heart Failure, published by Elsevier on behalf of the American College of Cardiology Foundation.
  • Impact Evaluation: The impact score of this journal is 11.8, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

SecretomeSkinTopoical
SecretomeSkinTopoical2752×1536 419 KB

Chronic exposure to ultraviolet radiation damages cellular power plants, known as mitochondria, causing them to leak genetic material into the cell interior and ignite severe tissue inflammation. Researchers have demonstrated that a non-invasive, topically applied liquid formulation containing the regenerative secretome of human umbilical cord stem cells reverses photoaging in sun-damaged skin. By reactivating mitophagy, the intracellular housekeeping mechanism that isolates and digests damaged organelles, this surface-applied therapy prevents mitochondrial DNA leakage and silences the inflammatory cGAS-STING alarm cascade, restoring skin hydration, elasticity, and dermal collagen architecture without requiring cellular injections.

Chronic solar exposure takes an undeniable toll on human skin, accelerating wrinkle formation, loss of structural elasticity, and barrier breakdown. While dermatologists have long relied on conventional topical treatments containing retinoids or antioxidants, these options frequently cause erythema and peeling or suffer from poor stability and limited tissue absorption. Now, researchers at Southern Medical University have demonstrated that a topical formulation containing the regenerative secretome of human umbilical cord mesenchymal stem cells can reverse established photoaging at the molecular level.

The therapy sidesteps the safety concerns, ethical controversies, and delivery hurdles associated with injecting living cells. Instead, the researchers developed a cell-free topical liquid preparation composed of the complete broth of signaling proteins, growth factors, and extracellular vesicles harvested from stem cell cultures. Applied daily as a surface treatment directly to ultraviolet-damaged skin, this topical cocktail delivered a restorative signal that penetrated the cutaneous barrier to rescue stressed epidermal cells.

At the center of this discovery is how the surface-applied formula restores mitochondrial housekeeping. Ultraviolet radiation severely damages mitochondria, the energy-producing powerhouses within skin cells. Healthy skin relies on a specialized recycling process called mitophagy to detect and dismantle these failing organelles. Chronic ultraviolet exposure paralyzes this clearance machinery. Deprived of proper cellular disposal, swollen and ruptured mitochondria leak fragments of their internal genetic material directly into the cellular interior.

Floating freely inside the cytoplasm, this misplaced mitochondrial DNA triggers a primitive immune alarm known as the cGAS-STING pathway. Misinterpreting internal mitochondrial leakage as an invading viral pathogen, this pathway unleashes a damaging cascade of inflammatory cytokines like interleukin-6 and interferon-beta, degrading the structural dermal scaffold and locking skin cells into permanent, non-dividing senescence.

Daily topical application of the stem cell secretome completely halted this destructive cascade. The topically delivered factors restored the expression of critical regulatory proteins, PINK1 and Parkin, re-establishing efficient autophagic disposal of crippled mitochondria. By clearing the structural debris before mitochondrial DNA could escape into the cytoplasm, the topical treatment silenced the cGAS-STING alarm system at its root.

The physiological turnaround was dramatic. The topical formula eliminated abnormal epidermal thickening, restored skin hydration and elasticity back to youthful baseline values, and halted the activation of matrix metalloproteinases that chew through dermal collagen. Notably, the surface application also suppressed circulating inflammatory markers throughout the bloodstream, demonstrating that treating the skin barrier topically dampens broader systemic inflammation. By proving that a surface-applied formulation can reboot intracellular organelle quality control and extinguish sterile tissue inflammation, this study points toward a new class of non-invasive, cell-free biologic treatments for environmental photoaging.

Actionable Insights

This study reveals that clearing damaged mitochondria and blocking the cytosolic DNA-sensing cascade are vital requirements for reversing sun-induced tissue aging. For individuals seeking practical longevity takeaways, the findings indicate that topical mesenchymal stem cell secretomes and condition-matched extracellular vesicles represent a promising cell-free therapeutic class.

The measured real-world magnitude of this topical intervention is exceptionally large. In animal models subjected to chronic ultraviolet exposure, topical secretome application reduced transepidermal water loss by 59.6 percent, reflecting an absolute reduction of 27.7 grams per square meter per hour and a standardized effect size of approximately d = 9.1, fully restoring the epidermal moisture barrier. Epidermal hydration improved by 78.4 percent, an absolute recovery of 21.0 arbitrary units (d ≈ 4.9), while skin elasticity gained 21.0 percentage points, an improvement of 57.5 percent (d ≈ 4.2). At the tissue architecture level, abnormal epidermal thickening was reduced by 64.2 percent (d ≈ 6.7).

While over-the-counter stem cell conditioned media products remain variable in potency, these data demonstrate that interventions designed to stimulate mitophagy or limit mitochondrial oxidative leakage can fundamentally alter cutaneous senescence trajectories.

Source / Context:

RapAdmin

ExerciseImmunity
ExerciseImmunity1920×1072 317 KB

Chinese researchers profiled the plasma metabolites, lipids, single-cell gene expression, and open chromatin of 86 healthy young adults, 40 who met WHO physical activity guidelines and 46 who reported literally zero purposeful exercise. Regular exercisers showed elevated fat-burning intermediates and antioxidant metabolites, broadly reduced circulating triglycerides and membrane phospholipids, and a striking epigenetic reprogramming of their immune cells. Monocytes and B cells had physically opened the DNA around their antigen presentation genes, while killer T cells and NK cells sat pre-loaded with effector machinery. Inflammatory signaling through resistin and IL-6 was damped down.

The health benefits of exercise are one of the least controversial findings in medicine. What has remained frustratingly vague is the molecular accounting. Most of what we know comes from short, tightly controlled training studies, often in athletes or patients, that measure a handful of markers before and after a treadmill session. That tells you about acute stress responses. It tells you much less about what a body looks like after years of simply being an active person.

A team drawing on the Chinese Immune Multi-omics Atlas went after the second question. From a cohort of 428 adults they selected the two extremes: 40 people who exercised at least three times a week and hit the WHO threshold of 150 minutes of moderate or 75 minutes of vigorous activity, and 46 people who reported zero minutes of deliberate exercise and named sitting as their default posture. Everyone was between 20 and 40, non-obese, non-smoking, and free of cancer or chronic infection. Then the researchers ran four separate technologies on their blood: targeted metabolomics on 321 small molecules, lipidomics on 718 lipid species, single-cell RNA sequencing on 1.3 million immune cells, and single-cell chromatin accessibility sequencing on another 644,000.

The metabolic picture was what an exercise physiologist would predict. Acylcarnitines, ketone bodies, and acetic acid were all higher in the active group, the signature of a body routinely pulling fat into mitochondria and burning it. Triglycerides fell across essentially every species measured. Antioxidant-associated molecules including betaine rose. Fasting glucose was lower, HDL cholesterol higher.

The immune findings are the genuinely new part. In the exercisers, monocytes and dendritic cells had not merely turned up expression of their antigen presentation genes. The chromatin around those genes, the physical packaging of the DNA, had been pried open. At the HLA-DQB1 promoter the accessibility difference carried a false discovery rate of roughly ten to the minus fifty-two. Transcription factors that drive antigen presentation, including SPI1, IRF1, and STAT1, showed elevated activity, while the AP-1 stress and inflammation family was suppressed. Killer CD8 T cells and mature NK cells showed the same pattern at their own effector genes, with the master regulators TBX21 and EOMES more accessible and granzymes and perforin more highly expressed. B cells joined in. When the team mapped cell-to-cell signaling, the active group showed amplified MHC class I and class II conversation between antigen-presenting cells and T cells, stronger interferon gamma flow, and weakened signaling through resistin and IL-6.

The proposed interpretation is that habitual exercise leaves the immune system in a state of primed alertness rather than chronic irritation, and that the priming is written epigenetically rather than just transcriptionally. That would explain why active people get fewer infections and respond better to vaccines. It would also, if it holds up, hand the field a set of chromatin-level biomarkers for what exercise adaptation actually is.

Actionable Insights

Nothing here changes the prescription. It changes what you should expect the prescription to do.

Meeting the standard WHO minimum, three sessions a week totaling 150 minutes of moderate work, was enough to produce the entire signature. No one in this study was an elite athlete. The comparison was simply people who train versus people who do nothing.

On magnitude, the paper reports only p-values, so effect sizes below are derived from those p-values and the group sizes. Translated into plain terms, a Cohen’s d of 0.5 means that if you picked one exerciser and one sedentary person at random, the exerciser would show the higher value about 64 percent of the time. Pure chance would be 50 percent.

  • Fat oxidation marker (O-adipoylcarnitine): d approximately 1.20, exerciser higher about 80 percent of the time. The single largest effect in the paper.
  • Betaine, an anti-inflammatory exercise mimetic: d approximately 0.79, about 71 percent.
  • Glutathione-synthesis proxy (2-hydroxybutyrate): d approximately 0.80, about 71 percent.
  • Ketone body (3-hydroxybutyrate): d approximately 0.60, about 67 percent.
  • Individual triglyceride species: d approximately 0.43 to 0.49, about 62 to 64 percent.

These are moderate to large by behavioral-intervention standards. But routine blood panel changes were modest: no biochemical index moved more than roughly 30 percent, read from the published figure. The metabolic and immune remodeling is real and broad.

Context and Source

  • Open Access Paper: Multiomics profiling identifies molecular and cellular signatures of regular exercise in human peripheral blood
  • Lead institutions: BGI Research, Shenzhen; State Key Laboratory of Genome and Multi-omics Technologies. Collaborating sites include Huazhong Agricultural University, Peking University Cancer Hospital, Chinese PLA General Hospital, Henan Provincial People’s Hospital, and Shanxi Medical University.
  • Country: China
  • Journal: Science Advances, volume 12, article eaeh0260, published 18 September 2026
  • Impact: The impact score of this journal is 13.9, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.